pupillary constriction occurs with intravenous administration of opioids such as sufentanil.However, few studies have investigated the pupillary effects of intrathecal （IT） sufentanil. It has previously been demonst...pupillary constriction occurs with intravenous administration of opioids such as sufentanil.However, few studies have investigated the pupillary effects of intrathecal （IT） sufentanil. It has previously been demonstrated that the cephalad spread within the cerebrospinal fluid of IT sufentanil results in side effects. There are two principal findings of the present study： （1） spinal sufentanil combined with low-dose of bupivacaine in patients with lower abdominal or lower extremity procedures induces a dose-dependent pupillary constriction that is far more sensitive than other centrally-mediated side effects; （2） the pupillary effect of IT sufentanil correlates closely with the adequacy of spinal anesthesia.展开更多
Animal experiments have confirmed that mesenchymal stem cells can inhibit motor neuron apoptosis and inflammatory factor expression and increase neurotrophic factor expression. Therefore, mesenchymal stem cells have b...Animal experiments have confirmed that mesenchymal stem cells can inhibit motor neuron apoptosis and inflammatory factor expression and increase neurotrophic factor expression. Therefore, mesenchymal stem cells have been shown to exhibit prospects in the treatment of amyotrophic lateral sclerosis. However, the safety of their clinical application needs to be validated. To investigate the safety of intrathecal injection of Wharton's jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy, 43 patients(16 females and 27 males, mean age of 57.3 years) received an average dose of 0.42 × 106 cells/kg through intrathecal administration at the cervical, thoracic or lumbar region depending on the clinical symptoms. There was a 2 month interval between two injections. The adverse events occurring during a 6-month treatment period were evaluated. No adverse events occurred. Headache occurred in one case only after first injection of stem cells. This suggests that intrathecal injection of Wharton's Jelly-derived mesenchymal stem cells is well tolerated in patients with amyotrophic lateral sclerosis. This study was approved by the Bioethical Committee of School of Medicine, University of Warmia and Mazury in Olsztyn, Poland(approval No. 36/2014 and approval No. 8/2016). This study was registered with the ClinicalTrials.gov(identifier: NCT02881476)on August 29, 2016.展开更多
文摘pupillary constriction occurs with intravenous administration of opioids such as sufentanil.However, few studies have investigated the pupillary effects of intrathecal （IT） sufentanil. It has previously been demonstrated that the cephalad spread within the cerebrospinal fluid of IT sufentanil results in side effects. There are two principal findings of the present study： （1） spinal sufentanil combined with low-dose of bupivacaine in patients with lower abdominal or lower extremity procedures induces a dose-dependent pupillary constriction that is far more sensitive than other centrally-mediated side effects; （2） the pupillary effect of IT sufentanil correlates closely with the adequacy of spinal anesthesia.
基金supported by Instytut Terapii Komórkowych w Olsztynie(Cell Therapies Institute,FamiCord Group)in Olsztyn(to MB,SM,and TS)
文摘Animal experiments have confirmed that mesenchymal stem cells can inhibit motor neuron apoptosis and inflammatory factor expression and increase neurotrophic factor expression. Therefore, mesenchymal stem cells have been shown to exhibit prospects in the treatment of amyotrophic lateral sclerosis. However, the safety of their clinical application needs to be validated. To investigate the safety of intrathecal injection of Wharton's jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy, 43 patients(16 females and 27 males, mean age of 57.3 years) received an average dose of 0.42 × 106 cells/kg through intrathecal administration at the cervical, thoracic or lumbar region depending on the clinical symptoms. There was a 2 month interval between two injections. The adverse events occurring during a 6-month treatment period were evaluated. No adverse events occurred. Headache occurred in one case only after first injection of stem cells. This suggests that intrathecal injection of Wharton's Jelly-derived mesenchymal stem cells is well tolerated in patients with amyotrophic lateral sclerosis. This study was approved by the Bioethical Committee of School of Medicine, University of Warmia and Mazury in Olsztyn, Poland(approval No. 36/2014 and approval No. 8/2016). This study was registered with the ClinicalTrials.gov(identifier: NCT02881476)on August 29, 2016.
